Last updated: February 16, 2026
What is the current market landscape for NDC 00169-4517?
NDC 00169-4517 corresponds to Bexagliflozin, an SGLT2 inhibitor developed for type 2 diabetes management. It is marketed under the brand Bexagliflozin by Ascendis Pharma, primarily in European countries. The drug is not yet broadly available in the U.S., nor has it received widespread regulatory approval globally.
The global diabetes drug market was valued at approximately $81 billion in 2021 and is projected to reach $112 billion by 2028, growing at a compounded annual growth rate (CAGR) of around 4.7%. SGLT2 inhibitors comprise a significant segment, with drugs like Jardiance (empagliflozin), Farxiga (dapagliflozin), and Invokana (canagliflozin) dominating market share. These drugs saw combined sales of over $12 billion in 2021.
Bexagliflozin's market potential depends on several factors:
- Regulatory approval: It is approved in Europe, subject to approval in other regions.
- Competitor landscape: Competes against established drugs with proven efficacy and safety profiles.
- Market penetration: Influenced by formulary inclusion, physician acceptance, and insurance coverage.
How much is Bexagliflozin likely to cost upon commercialization?
In Europe, drugs like dapagliflozin and empagliflozin retail around €30-€50 per month per patient. These prices vary based on country and insurance arrangements.
Given the pricing landscape:
| Drug |
Approximate Monthly Cost |
Market Share (2021) |
Notes |
| Jardiance |
€45 |
40% |
Leading in the SGLT2 inhibitor segment |
| Farxiga |
€40 |
25% |
Strong presence in North America |
| Invokana |
€45 |
15% |
Approved in multiple markets |
| Bexagliflozin |
Estimated €35-€50 |
Not yet established |
Pending approval, price based on comparables |
If Bexagliflozin gains approval and market entry, its price will likely align with competitors if it demonstrates non-inferior efficacy and safety.
What are the revenue projections based on current data?
Market penetration depends on:
- Timeline to approval: Assuming it completes pivotal trials by 2023-2024.
- Market acceptance: Expected initial uptake at 1-3% of the global SGLT2 market in first year.
- Pricing strategy: Similar to current SGLT2 inhibitors.
Sample projection assuming a conservative scenario:
| Year |
Estimated Patients (Europe, initial) |
Revenue (USD million) |
Assumptions |
| 2024 |
50,000 |
$30 million |
Entry in European markets, price €40/month |
| 2025 |
150,000 |
$90 million |
Growth fueled by new indications, wider approval, continued market penetration |
| 2026 |
300,000 |
$180 million |
Expanded approval, increased physician adoption |
In the U.S., initial uptake might be limited due to regulatory delays, but with eventual approval, revenues could scale proportionally to the market size, estimated at over $15 billion annually for the global market.
What are the key challenges impacting Bexagliflozin's commercial success?
- Regulatory hurdles: Pending approvals delay market entry.
- Competitive pressure: Established drugs have significant brand loyalty and proven safety profiles.
- Pricing pressures: Payers favor cost-effective options; premium pricing risks limited reimbursement.
- Clinical differentiation: Demonstrating distinct benefits over existing therapies (e.g., improved cardiovascular, renal outcomes) is vital.
What are the likely pricing strategies and margins?
Pricing will be influenced by:
- Market dynamics: Similar drugs are priced around €30-€50 monthly.
- Reimbursement policies: In Europe, national health systems negotiate prices; in the U.S., PBMs and insurers set formulary status.
- Cost structure: Manufacturing costs for small-molecule drugs typically range from $2-5 per dose; margin expectations aim for 60-70%.
Assuming a wholesale price of €40-€45, gross margins could be 70% or higher under optimized supply chains.
Key Takeaways
- Bexagliflozin (NDC 00169-4517) targets an established market segment with significant growth potential.
- Its pricing will approximate current SGLT2 inhibitors, around €30-€50 per month.
- Revenue projections vary with approval timelines, market penetration, and payer coverage, potentially reaching hundreds of millions USD annually within a few years post-approval.
- Challenges include competition, regulatory delays, and payer negotiations.
- Early differentiation through clinical benefits will be critical for market share expansion.
FAQs
1. When is Bexagliflozin expected to be available in the U.S.?
Approval timelines are uncertain; clinical trials are underway, but FDA approval could take until 2024-2025 if successful.
2. How does Bexagliflozin compare to existing SGLT2 inhibitors?
Preliminary data suggest similar efficacy; ongoing trials focus on cardiovascular and renal benefits to differentiate it.
3. What factors influence its pricing?
Market competitiveness, clinical differentiation, payer negotiations, and regional pricing policies.
4. What is the potential market share in the global diabetes segment?
Initially, less than 2%; with successful adoption, it could command 5-10% of the SGLT2 inhibitor segment.
5. How fast could revenue growth occur post-approval?
Rapid growth within 2-3 years, assuming regulatory approval, favorable pricing, and clinical acceptance.
Sources
[1] MarketWatch, "Diabetes Drugs Market Size," 2021.
[2] EvaluatePharma, "Top-Selling Diabetes Drugs," 2021.
[3] European Medicines Agency, "Bexagliflozin Approval Status," 2022.
[4] IQVIA, "Global Diabetes Market Report," 2022.
